Recursion Pharmaceuticals, Inc. RXRX Accrued liabilities
Accrued liabilities at other companies
Other financials
Where this comes from
Reported directly by Recursion Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOtherAccruedLiabilities.
The official record: Recursion Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Recursion Pharmaceuticals, Inc.'s accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Recursion Pharmaceuticals, Inc.'s accrued liabilities?
- Recursion Pharmaceuticals, Inc. (RXRX) reported accrued liabilities of -$18.45M in Q1 2026.
- How has Recursion Pharmaceuticals, Inc.'s accrued liabilities changed year-over-year?
- Recursion Pharmaceuticals, Inc.'s accrued liabilities increased by 30.6% year-over-year, from -$26.59M to -$18.45M.